Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-week, Randomized, Single-blind, Placebo-controlled, Multi-centre, Parallel Group, Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 After 4 and 12-weeks of Treatment in Patients With Coronary Artery Disease (CAD)

Next Previous
X
Search
Trial Profile

A 12-week, Randomized, Single-blind, Placebo-controlled, Multi-centre, Parallel Group, Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 After 4 and 12-weeks of Treatment in Patients With Coronary Artery Disease (CAD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atuliflapon (Primary)
  • Indications Coronary artery disease; Myocardial infarction
  • Focus Biomarker; Pharmacodynamics
  • Acronyms FLAVOUR
  • Sponsors AstraZeneca AB

    • Most Recent Events

    • 15 Oct 2022 Results published in the International Journal of Cardiology
    • 17 May 2021 Primary endpoint (Percentage change from baseline in levels of urine-leukotriene E4 (u-LTE4) has been met according to the results presented at the 70th Annual Scientific Session of the American College of Cardiology
    • 17 May 2021 Results presented at the 70th Annual Scientific Session of the American College of Cardiology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top